VR Adviser’s Century Therapeutics IPSC Stock Holding History

VR Adviser’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.7M	Buy	+8,695,652	New	+$18.3M	0.73%	25
2025 Q2	–	Sell	-2,498,069	Closed	-$1.19M	–	34
2025 Q1	$1.19M	Sell	2,498,069 -1,459,117	-37%	-$1.1M	0.1%	34
2024 Q4	$4M	Sell	3,957,186 -1,432,073	-27%	-$1.95M	0.27%	32
2024 Q3	$9.22M	Hold	5,389,259	–	–	0.48%	31
2024 Q2	$13.7M	Buy	5,389,259 +1,984,126	+58%	+$6.27M	0.88%	28
2024 Q1	$14.2M	Buy	+3,405,133	New	+$14.4M	0.68%	32

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser's IPSC Position: Q1 2026 in Review

VR Adviser opened a new position in Century Therapeutics (IPSC) in Q1 2026: 8,695,652 shares worth $19.7M. The stake represents 0.73% of the portfolio and ranks #25 among its holdings. This is a return to the name: VR Adviser previously reported a position in IPSC as recently as Q1 2025.

VR Adviser first reported a position in IPSC in Q1 2024 and has held it in 6 quarters since. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

VR Adviser held 8,695,652 shares of Century Therapeutics worth $19.7M as of Q1 2026.
Century Therapeutics was a new VR Adviser position in Q1 2026.
Century Therapeutics made up 0.73% of VR Adviser's portfolio in Q1 2026, its #25 holding.
VR Adviser first reported a position in Century Therapeutics in Q1 2024 and has held it in 6 quarters since.
72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.